Detalhe da pesquisa
1.
Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Nature
; 599(7886): 679-683, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34759319
2.
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
N Engl J Med
; 386(3): 241-251, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534430
3.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
4.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Lancet Oncol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710187
5.
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Lancet Oncol
; 25(4): 439-454, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547891
6.
Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
Oncologist
; 29(1): 15-24, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37616543
7.
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
N Engl J Med
; 384(25): 2371-2381, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34096690
8.
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Future Oncol
; 20(3): 113-120, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010044
9.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
10.
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med
; 383(13): 1207-1217, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32955176
11.
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.
Br J Cancer
; 126(6): 889-898, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34963703
12.
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.
Cancer
; 126(22): 4967-4974, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32809222
13.
ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
Oncologist
; 25(8): 641-649, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32558067
14.
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply.
N Engl J Med
; 386(18): 1770-1771, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507496
15.
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
Cancer
; 125(24): 4380-4387, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31469421
16.
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.
Acta Oncol
; 58(11): 1634-1639, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31347936
17.
Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E.
Oncologist
; 23(2): 150-154, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29146616
18.
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Invest New Drugs
; 35(6): 742-750, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28281183
19.
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Histopathology
; 70(3): 402-411, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27599111
20.
Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors.
Neuroendocrinology
; 104(3): 209-222, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27082107